Back to Awarded Treatment Trials


Awarded Trial: 06TGF-996

Grant ID

06TGF-996

Illness

Bipolar Disorder

Primary Drug/Intervention

N-acetylcysteine

Primary Dosage

2 g/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Berk

Sample Size

150

Duration of Study Period for Each Subject

26 weeks

Outcome Measurements

PANSS, MINI PLUS-BP, T.I.M.E, Q-LES-Q (short form), BDRS

Results

N-acetylcysteine (NAC), a precursor of glutathione, was given 1 mg twice daily for 8 wks to 156 BP depressed individuals in an open-label trial, with improvement in symptoms as assessed by MADRS, YMRS, and CGI. After 8 wks, 101 of the patients were randomized to NAC 1 mg twice daily or placebo for a maintenance phase of approximately 7 months. During the maintenance phase, there was no difference in relapse rates between the groups.

Publication

Submitted for publication

Link

N/A

PI Name

Michael Berk

Degree

MD

Center

Mental Health Research Institute

Institution

University of Melbourne

Address

155 Oak Street

City or Town

Parkville

State or Province

Victoria

Zip or Postal Code

3052

Country

Australia

Email Address

mikebe@barwonhealth.org.au